Potential role of vitamin D deficiency on Fabry cardiomyopathy
Open Access
- 19 October 2013
- journal article
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 37 (2) , 289-295
Abstract
Patients with Fabry disease frequently develop left ventricular (LV) hypertrophy and renal fibrosis. Due to heat intolerance and an inability to sweat, patients tend to avoid exposure to sunlight. We hypothesized that subsequent vitamin D deficiency may contribute to Fabry cardiomyopathy. This study investigated the vitamin D status and its association with LV mass and adverse clinical symptoms in patients with Fabry disease. 25‐hydroxyvitamin D (25[OH]D) was measured in 111 patients who were genetically proven to have Fabry disease. LV mass and cardiomyopathy were assessed by magnetic resonance imaging and echocardiography. In cross‐sectional analyses, associations with adverse clinical outcomes were determined by linear and binary logistic regression analyses, respectively, and were adjusted for age, sex, BMI and season. Patients had a mean age of 40 ± 13 years (42 % males), and a mean 25(OH)D of 23.5 ± 11.4 ng/ml. Those with overt vitamin D deficiency (25[OH]D ≤ 15 ng/ml) had an adjusted six fold higher risk of cardiomyopathy, compared to those with sufficient 25(OH)D levels >30 ng/ml (p = 0.04). The mean LV mass was distinctively different with 170 ± 75 g in deficient, 154 ± 60 g in moderately deficient and 128 ± 58 g in vitamin D sufficient patients (p = 0.01). With increasing severity of vitamin D deficiency, the median levels of proteinuria increased, as well as the prevalences of depression, edema, cornea verticillata and the need for medical pain therapy. In conclusion, vitamin D deficiency was strongly associated with cardiomyopathy and adverse clinical symptoms in patients with Fabry disease. Whether vitamin D supplementation improves complications of Fabry disease, requires a randomized controlled trial.Keywords
This publication has 32 references indexed in Scilit:
- Cardiomyocyte-Specific Deletion of the Vitamin D Receptor Gene Results in Cardiac HypertrophyCirculation, 2011
- Preventing progression of cardiac hypertrophy and development of heart failure by paricalcitol therapy in ratsCardiovascular Research, 2011
- Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trialThe Lancet, 2010
- Hypocalcemic Rickets and Dilated Cardiomyopathy: Case Reports and Review of LiteraturePediatric Cardiology, 2009
- Expression of the Vitamin D Receptor Is Increased in the Hypertrophic HeartHypertension, 2008
- Vitamin D and Human Health: Lessons from Vitamin D Receptor Null MiceEndocrine Reviews, 2008
- Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapyJournal Of Nephrology, 2008
- Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animalsProceedings of the National Academy of Sciences, 2007
- Impact of Enzyme Replacement Therapy on Cardiac Morphology and Function and Late Enhancement in Fabry’s CardiomyopathyThe American Journal of Cardiology, 2006
- Mouse Vitamin D-24-Hydroxylase: Molecular Cloning, Tissue Distribution, and Transcriptional Regulation by 1α,25-Dihydroxyvitamin D3*Endocrinology, 1997